---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000054"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:20:59.367939+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Xeris appoints James Brady to board, directors Ricki Fairley and John Schmid depart

## Summary
- Ricki Fairley resigned effective March 28, 2025; no disagreement with company.
- John Schmid will not stand for reelection at 2025 Annual Meeting; board to reduce to eight members.
- James Brady appointed as Class I director, will chair Audit Committee if reelected.
- Brady brings 30+ years at AstraZeneca, most recently CFO of MedImmune; also serves on Verona Pharma (VRNA) board.
- Brady received initial equity grant of 100,000 RSUs under non-employee director compensation plan.

## SEC filing metadata
- accession: 0001867096-25-000054
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/0001867096-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/xers-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000054
- JSON: https://secwatch.observer/filing/0001867096-25-000054.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000054.txt

## Key facts
- Executive change
  Ricki Fairley resigned as Director at Xeris Biopharma Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/0001867096-25-000054-index.htm
- Executive change
  James Brady was appointed as Director at Xeris Biopharma Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/0001867096-25-000054-index.htm
- Executive change
  John Schmid departed as Director at Xeris Biopharma Holdings, Inc..
  - Action: not stand for reelection
  - Role: Director
  source text: On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/0001867096-25-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.